BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32116204)

  • 21. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
    Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
    Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of NANOG Mediates the Inhibitory Effect of Aspirin on Tumor Growth and Stemness in Colorectal Cancer.
    Wang H; Liu B; Wang J; Li J; Gong Y; Li S; Wang C; Cui B; Xue X; Yang M; Fan W; Kang Z; Kamran M; Xu J; Tian P; Luo Y; Hou Z; Dong L; Ren Y; Li M; Wen Q; Cheng W; Xu L; Wang L; Liu Q
    Cell Physiol Biochem; 2017; 44(3):1051-1063. PubMed ID: 29179207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
    Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
    J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant
    Nishi K; Luo H; Ishikura S; Doi K; Iwaihara Y; Wills L; Baillie GS; Sakata T; Shirasawa S; Tsunoda T
    Anticancer Res; 2017 Jul; 37(7):3833-3839. PubMed ID: 28668883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
    Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
    Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human Endogenous Retrovirus-H and K Expression in Human Mesenchymal Stem Cells as Potential Markers of Stemness.
    Mareschi K; Montanari P; Rassu M; Galliano I; Daprà V; Adamini A; Castiglia S; Fagioli F; Bergallo M
    Intervirology; 2019; 62(1):9-14. PubMed ID: 31104062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
    Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
    ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
    Hung WC; Lee DY; Chiang EI; Syu JN; Chao CY; Yang MD; Tsai SY; Tang FY
    PLoS One; 2020; 15(11):e0241186. PubMed ID: 33137095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Active Compound of
    Song J; Seo H; Kim MR; Lee SJ; Ahn S; Song M
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32580297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
    Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
    Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
    Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer.
    Zhong L; Wang R; Wang Y; Peng S; Ma Y; Ding S; Yang H; Chen S; Luo X; Wang W
    Neoplasia; 2020 Sep; 22(9):365-375. PubMed ID: 32629177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD95 ligand induces senescence in mismatch repair-deficient human colon cancer via chronic caspase-mediated induction of DNA damage.
    Raats DA; Frenkel N; van Schelven SJ; Rinkes IH; Laoukili J; Kranenburg O
    Cell Death Dis; 2017 Mar; 8(3):e2669. PubMed ID: 28300842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of Nanog and Sox-2 genes following ectopic expression of Oct-4 in amniotic fluid mesenchymal stem cells.
    Wang KH; Kao AP; Chang CC; Lin TC; Kuo TC
    Biotechnol Appl Biochem; 2015; 62(5):591-7. PubMed ID: 25385323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.
    Conti A; Majorini MT; Elliott R; Ashworth A; Lord CJ; Cancelliere C; Bardelli A; Seneci P; Walczak H; Delia D; Lecis D
    Oncotarget; 2015 May; 6(13):10994-1008. PubMed ID: 26028667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.
    Chu PC; Lin PC; Wu HY; Lin KT; Wu C; Bekaii-Saab T; Lin YJ; Lee CT; Lee JC; Chen CS
    Oncogene; 2018 Jun; 37(25):3440-3455. PubMed ID: 29559746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.